



jc972 U.S. PTO  
09/764348  
01/19/01



Patents Office  
Government Buildings  
Hebron Road  
Kilkenny

I HEREBY CERTIFY that annexed hereto is a true copy of  
documents filed in connection with the following patent  
application:

Application No. S980594

Date of Filing 21 July 1998

Applicant ALLTRACEL PHARMACEUTICALS PLC, an  
Irish company of 87 Quinns Road, Shankill, County  
Dublin, Ireland.

Dated this 7 day of December, 2000.

An officer authorised by the  
Controller of Patents, Designs and Trademarks.

## REQUEST FOR THE GRANT OF A PATENT

## PATENTS ACT, 1992

The Applicant(s) named herein hereby request(s)  
\_\_\_\_ the grant of a patent under Part II of the Act

X the grant of a short-term patent under Part III of the Act on the basis of the information furnished hereunder.

1. Applicant(s)

Name Alltracel Pharmaceuticals PLC

Address 87 Quinns Road  
Shankill  
County Dublin  
Ireland

Description/Nationality

An Irish company

2. Title of Invention

## “Formulations”

3. Declaration of Priority on basis of previously filed application(s) for same invention (Sections 25 & 26)

Previous filing date      Country in or for      Filing No.  
which filed

4. Identification of Inventor(s)

Name(s) of person(s) believed  
by Applicants(s) to be the inventor(s)

Name: Ivan Santar, a citizen of the Czech Republic  
Address: Travniky 1006, CZ-6602 Predklasteri, Czech Republic

Name: Frantisek Kiss, a citizen of the Czech Republic  
Address: Bednarova 20a, CZ-61900 Brno, Czech Republic

Name: Jiri Briestensky, a citizen of the Czech Republic  
Address: Skolska 413, CZ-50343 Cernilov, Czech Republic

5. Statement of right to be granted a patent (Section 17(1)(b))

The Applicant derives the rights to the invention by virtue of Agreements dated December 23, 1996 and December 30, 1996.

6. Items accompanying this Request – tick as appropriate

- (i)  prescribed filing fee (£50.00)
- (ii)  specification containing a description and claims  
 specification containing a description only  
 Drawings referred to in description or claims
- (iii)  An abstract
- (iv)  Copy of previous application (s) whose priority is claimed
- (v)  Translation of previous application whose priority is claimed
- (vi)  Authorisation of Agent (this may be given at 8 below if this Request is signed by the Applicant (s))

7. Divisional Application (s)

The following information is applicable to the present application which is made under Section 24 –

Earlier Application No: .....

Filing Date: .....

8. Agent

The following is authorised to act as agent in all proceedings connected with the obtaining of a patent to which this request relates and in relation to any patent granted -


<u>Name</u>	<u>Address</u>
John A. O'Brien & Associates	The address recorded for the time being in the Register of Patent Agents, and currently Third Floor, Duncairn House, 14 Carysfort Avenue, Blackrock, Co. Dublin, Ireland.


9. Address for Service (if different from that at 8)

As above

Signed

Date July 21, 1998

 JOHN A. O'BRIEN & ASSOCIATES

Introduction

5 The invention relates to polyanhydroglucuronic acids and salts thereof. The term polyanhydroglucuronic acid and salts thereof as used herein includes copolymers thereof, especially with anhydroglucose.

10 Co-pending patent application PCT IE98/00003 describes a haemostatically active aerosol composition of polyanhydroglucuronic acid and/or acceptable salts thereof.

15 Co-pending patent application PCT IE98/00004 describes particular polyanhydroglucuronic acids and salts thereof and a method of preparing such compounds.

In particular therefore, the term polyanhydroglucuronic acids and salts thereof includes the acids and salts referred to in our co-pending applications mentioned above.

20 This invention relates especially to formulations incorporating polyanhydroglucuronic acids and salts thereof.

Statements of Invention

25 According to the invention there is provided a formulation comprising tablets or pellets of polyanhydroglucuronic acids and salts thereof.

30 Most preferably, the polyanhydroglucuronic acids and salts thereof are those described in co-pending PCT IE98/00004.

Detailed Description

We have found that polyanhydrogluronic acid and salts thereof particularly as described in co-pending Application PCT IE98/00004 in both the powder or fibre 5 form has an open surface with a high degree of porosity. It can therefore be pressed by conventional methods into the form of tablets or pellets without the necessity of using other auxiliary adjuvants.

10 The tablets may for example be used in the gastrointestinal tract for protection of abdominal and/or intestinal mucous tissue against erosion, for control of bleeding from peptic and duodenal ulcers, for control of hydrochloric acid and pepsins secretion from the abdominal wall. The tablet form is particularly suitable for these purposes compared to use of a powder, because it provides protection against partial degradation of the material by enzymes present in vivo, for 15 example in saliva.

20 The tablet formulation may include other active substances to obtain a dual or multi action. Such additional active substances may, for example be compounds containing  $\text{Bi}^{3+}$   $\text{Al}^{3+}$  or  $\text{Mg}^{2+}$  ions which are useful in treatment of disorders in the gastric system, especially as antacids. Alternatively or additionally the formulation may include other active compounds such as histamine  $\text{H}_2$  – receptor antagonists, for example ranitidine or cimetidine.

25 It will be appreciated that the tablets may include pharmaceutically acceptable adjuvants and/or excipients in some cases.

The invention is not limited to the embodiments hereinbefore described which may be varied in detail.